Patents Assigned to Merck Patents GmbH
  • Patent number: 11065255
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 20, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Patent number: 11065253
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: July 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Publication number: 20210214606
    Abstract: The present invention relates to a method for preparing a nanosized light emitting semiconductor material.
    Type: Application
    Filed: October 10, 2018
    Publication date: July 15, 2021
    Applicant: Merck Patent GmbH
    Inventors: Artyom SEMYONOV, Ehud SHAVIV
  • Patent number: 11060029
    Abstract: The invention relates to a liquid-crystalline medium having a nematic phase comprising one or more compounds of formula B wherein the parameters have the meaning given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type and to the use of the compounds of formula B for improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 13, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Atsutaka Manabe, Constanze Brocke
  • Patent number: 11060626
    Abstract: A fluid distributor valve (1) for repartitioning an inlet fluid stream (Z) into two outlet fluid streams (X, Y), comprising an inlet port (10), two outlet ports (11, 12), a first and a second valve mechanism (13, 14), one arranged upstream each outlet port (11, 12), wherein each valve mechanism (13, 14) comprises a valve body (15, 16) slidable in a cylindrical valve bore (17) in reciprocating strokes through a valve shaft (18), wherein the valve body (15, 16) includes a first portion (15a, 16a) that is formed with a progressively changing diameter so as to reduce a valve gap between the valve bore inner peripheral wall and the valve body outer peripheral wall at a plane (A, B) perpendicular to the stroke direction, in a regular operating range of the valve mechanism (13, 14), from a maximum valve gap to a minimum valve gap, to reduce or increase the flow rate through the gap towards the associated outlet port (11, 12) upon the relative movement, and wherein at least one of the valve bodies (15, 16) of the val
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: July 13, 2021
    Assignee: Merck Patent GmbH
    Inventor: Laurent Moreau
  • Patent number: 11058769
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
  • Patent number: 11059995
    Abstract: [Problem] To provide a film forming composition curable at low temperature and a film forming method using the same. [Means for Solution] A film forming composition comprising a polysilazane, an organic solvent and aspecific additive, and a film forming method comprising applying it on a substrate and curing. The specific additive is selected from the group consisting of (A) guanidines substituted by a hydrocarbylgroup, (B) crown ether amines containing oxygen and nitrogen as a member thereof, (C) cycloalkanes having an amino-substituted polycyclic structure, (D) oximes substituted by a hydrocarbyl group, and (E) imidazolines.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: July 13, 2021
    Assignee: Merck Patent GmbH
    Inventors: Go Noya, Masahiko Kubo, Noboru Satake, Yoshio Nojima, Yuki Ozaki, Toshiya Okamura
  • Patent number: 11063221
    Abstract: The present application relates to a substituted benzanthracene compound of a formula (I) or (II). The application furthermore relates to an electronic device which comprises the said benzanthracene compound.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: July 13, 2021
    Assignee: Merck Patent GmbH
    Inventors: Holger Heil, Lara-Isabel Rodriguez, Beate Burkhart, Sebastian Meyer
  • Patent number: 11063227
    Abstract: An electronic switching element is described having, in sequence, a first electrode, a molecular layer bonded to a substrate, and a second electrode. The molecular layer contains compounds of formula I, R1-(A1-Z1)r—B1—(Z2-A2)s-Sp-G, wherein A1, A2, B1, Z1, Z2, Sp, G, r, and s are as defined herein, in which a mesogenic radical is bonded to the substrate via a spacer group, Sp, by means of an anchor group, G. The switching element is suitable for production of components that can operate as a memristive device for digital information storage.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: July 13, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Andreas Ruhl, Marc Tornow, Achyut Bora
  • Patent number: 11059974
    Abstract: [Problem] To provide a composition comprising polycarbosilane, which has excellent filling property, can form a film at a lower temperature, and makes electrical property of the produced film excellent. [Means for Solution] A silicon carbonaceous film forming composition comprising polycarbosilane and a solvent, wherein the ratio of the integrated intensity at 3.92 to 4.20 ppm to the integrated intensity at 3.60 to 5.50 ppm in the H-NMR spectrum of said polycarbosilane is 27 to 50%.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: July 13, 2021
    Assignee: Merck Patent GmbH
    Inventor: Toshiya Okamura
  • Patent number: 11059986
    Abstract: The present invention relates to a composition comprising a nanosized light emitting material, and method for preparing of said composition. The present invention further relates to a light luminescent medium, a light emitting device, the present invention further more relates to method for preparing of a composition and to method for preparing of a light emitting medium.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 13, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Masaki Hasegawa, Noriyuki Matsuda
  • Publication number: 20210207029
    Abstract: A liquid-crystalline medium having a nematic phase containing one or more compounds of formula D the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type and the use of the compounds of formula D for improvement of the contrast and/or response times of a liquid-crystalline medium which contain one or more additional mesogenic compounds, as well as certain compounds of formula D.
    Type: Application
    Filed: December 18, 2020
    Publication date: July 8, 2021
    Applicant: Merck Patent GmbH
    Inventors: Sven Christian LAUT, Martina WINDHORST, Constanze BROCKE
  • Publication number: 20210205238
    Abstract: The invention relates to injectable pharmaceutical compositions comprising epinephrine, an antioxidant selected from the group consisting of sodium metabisulfite, sodium sulfite and sodium bisulfite, tartrate, a tonicity regulating agent, EDTA or Na2EDTA*2H2O and pH 3.0-4.5.
    Type: Application
    Filed: October 8, 2018
    Publication date: July 8, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Steffen AUGUSTIN, Thomas Artur Hendrik HERBST, Ulrich EMDE
  • Publication number: 20210207079
    Abstract: The present invention relates to a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to cell culture media with improved solubility without changing the chemical composition.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Applicant: Merck Patent GmbH
    Inventors: Joerg VON HAGEN, Nikolai STANKIEWICZ, Anke SIMON
  • Patent number: 11056652
    Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. Furthermore, the present invention relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: July 6, 2021
    Assignee: Merck Patent GmbH
    Inventors: Jochen Pfister, Frank Stieber, Elvira Montenegro, Teresa Mujica-Fernaud, Frank Voges
  • Patent number: 11053233
    Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 6, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuníng, Marco Poma, Edoardo Burini
  • Patent number: 11053442
    Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 6, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Kevin Adlem, Alex Davis, Joseph Sargent, Ian Charles Sage, Edward Plummer, Izumi Saito, Rocco Fortte, Helga Haas, Lars Lietzau
  • Patent number: 11056656
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 6, 2021
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Jonas Kroeber, Dominik Joosten, Aurélie Ludemann, Tobias Grossmann
  • Publication number: 20210198566
    Abstract: The present invention relates to a formulation comprising at least a polymer, a particle, and an organic solvent.
    Type: Application
    Filed: May 21, 2019
    Publication date: July 1, 2021
    Applicant: Merck Patent GmbH
    Inventor: Masaki HASEGAWA
  • Publication number: 20210198257
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN